(2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;3-[formyl(hydroxy)amino]propylphosphonic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;3-[formyl(hydroxy)amino]propylphosphonic acid
• 化学式: C22H43ClN3O10PS
• 分子量: 608.1
• InChiKey: JFYYQKHTMFHERN-XJQDNNTCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.21
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  226
• 氢给体数：
  7
• 氢受体数：
  12

文献信息

• Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
  申请人：——

  公开号：US20040235784A1

  公开（公告）日：2004-11-25

  Disclosed are pharmaceutical preparations for use in the therapeutical and prophylactic treatment of bacterial and parasitic infections, especially malaria. The preparations contain as active substances 3-N-formyl-hydroxylaminopropyl phosphonic acid derivatives or 3-N-acetylhydroxylaminopropyl phosphonic acid derivatives and may be combined with other pharmaceutical active agents and/or other pharmaceutically acceptable excipients. Also disclosed are methods of treatments using such preparations.

  所公开的是用于治疗和预防细菌和寄生虫感染，特别是疟疾的药物制剂。这些制剂含有作为活性物质的 3-N-甲酰羟基氨丙基膦酸衍生物或 3-N-乙酰羟基氨丙基膦酸衍生物，并可与其他药物活性剂和/或其他药学上可接受的赋形剂结合使用。还公开了使用此类制剂的治疗方法。
• COMBINATION PREPARATIONS OF 3-N-FORMYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES OR 3-N-ACETYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES TOGETHER WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS
  申请人：Jomaa Pharmaka GmbH

  公开号：US20150190418A1

  公开（公告）日：2015-07-09

  The invention relates to pharmaceutical combination preparations for use in the therapeutical and prophylactic treatment of bacterial and parasitic infections, especially malaria. The inventive preparations contain as the active substances 3-N-formyl-hydroxylaminopropyl phosphonic acid derivatives or 3-N-acetylhydroxylaminopropyl phosphonic acid derivatives combined with other pharmaceutical active agents.